Lower Levels of Tau Marker Seen With Aduhelm in Phase 3 Trials

Lower Levels of Tau Marker Seen With Aduhelm in Phase 3 Trials

312319

Lower Levels of Tau Marker Seen With Aduhelm in Phase 3 Trials

Treatment with Aduhelm (aducanumab) showed a significant correlation with lower blood levels of p-tau181, a disease biomarker, and lesser cognitive and functional decline in Alzheimer’s patients, according to a recent data analysis of two Phase 3 clinical trials. The data, analyzed from around 7,000 blood samples collected from more than 1,800 patients who participated in the EMERGE (NCT02484547) and ENGAGE (NCT02477800) trials, were presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD), held Nov. 9–12. “We…

You must be logged in to read/download the full post.